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172The Prognostic Value of Pre-Operative and Post-Operative B-Type Natriuretic Peptides
in Patients Undergoing Noncardiac SurgeryB-Type Natriuretic Peptide and N-Terminal Fragment of Pro-B-Type Natriuretic Peptide:
A Systematic Review and Individual Patient Data Meta-AnalysisObjectives TSeehe objective of this study was to determine whether measuring post-operative B-type natriuretic peptides (NPs)
(i.e., B-type natriuretic peptide [BNP] and N-terminal fragment of proBNP [NT-proBNP]) enhances risk stratification in
adult patients undergoing noncardiac surgery, in whom a pre-operative NP has been measured.Background Pre-operative NP concentrations are powerful independent predictors of perioperative cardiovascular complications,
but recent studies have reported that elevated post-operative NP concentrations are independently associated with
these complications. It is not clear whether there is value in measuring post-operative NP when a pre-operative
measurement has been done.Methods We conducted a systematic review and individual patient data meta-analysis to determine whether the addition of
post-operative NP levels enhanced the prediction of the composite of death and nonfatal myocardial infarction at 30
and 180 days after surgery.Results Eighteen eligible studies provided individual patient data (n ¼ 2,179). Adding post-operative NP to a risk prediction
model containing pre-operative NP improved model fit and risk classification at both 30 days (corrected quasi-
likelihood under the independence model criterion: 1,280 to 1,204; net reclassification index: 20%; p < 0.001)
and 180 days (corrected quasi-likelihood under the independence model criterion: 1,320 to 1,300; net
reclassification index: 11%; p ¼ 0.003). Elevated post-operative NP was the strongest independent predictor of the
primary outcome at 30 days (odds ratio: 3.7; 95% confidence interval: 2.2 to 6.2; p < 0.001) and 180 days (odds
ratio: 2.2; 95% confidence interval: 1.9 to 2.7; p < 0.001) after surgery.Conclusions Additional post-operative NP measurement enhanced risk stratification for the composite outcomes of death or
nonfatal myocardial infarction at 30 days and180 days after noncardiac surgery compared with a pre-operative NP
measurement alone. (J AmColl Cardiol 2014;63:170–80)ª2014by theAmericanCollege of Cardiology FoundationWorldwide, an estimated 10 million adults annually expe-
rience significant myocardial injury after noncardiac surgery,
as suggested by the post-operative peak troponin T
measurement in a large (n ¼ 1,513) international cohort
study (1). To mitigate this risk, strategies are needed that
provide appropriate pre-operative medical investigation and
preparation, surgical interventions (e.g., open vs. endoscopic
surgery), and post-operative surveillance and management.
However, the success of such interventions depends largely
on the ability of clinicians to accurately identify patients at
risk of cardiovascular complications.page 181B-type natriuretic peptides (NPs) are released from the
myocardium in response to multiple physiological stimuli, in-
cluding ischemia, myocardial stretch, inflammation, and other
neuroendocrine stimuli (2,3), and multiple studies have dem-
onstrated that elevated pre-operative NP concentrations are
powerful independent predictors of perioperative cardiovascular
complications (i.e., mortality, myocardial infarction [MI], and
heart failure) (4,5). In vascular surgical cases, pre-operative NP
risk stratification outperforms traditional clinical risk strati-
fication (6), and the European Society of Cardiology and
European Society of Anesthesiology guidelines for pre-
operative cardiac risk assessment have recommended that pre-operative NP measurement be considered in high-risk
noncardiac surgery cases (7).
However, recent studies have reported that elevated post-
operative NP concentrations are independently associated
with post-operative cardiovascular complications (8,9). In
view of the improved pre-operative risk stratification
provided by pre-operative NP measurement, it is not clear
whether there would be any advantage to measuring post-
operative NP in these patients.
We conducted a systematic review and individual patient
meta-analysis to determine, in adults undergoing noncardiac
surgery, whether adding post-operative NP measurements to
pre-operative values enhances a clinician’s ability to predict
a composite of death and nonfatal MI at 30 days
and 180 days after noncardiac surgery. The study protocol
(CRD42012002683) was registered with an international
prospective register of systematic reviews (PROSPERO).Methods
Systematic review methodology. Studies were considered
eligible if they measured B-type natriuretic peptide (BNP) or
N-terminal fragment of proBNP (NT-proBNP) preopera-
tively and postoperatively (i.e., <8 days after noncardiac
surgery) on the same patient. Our primary outcome was
a composite of mortality or nonfatal MI. Studies were
Abbreviations
and Acronyms
AUC = area under the curve
BNP = B-type natriuretic
peptide
CI = confidence interval
IQR = interquartile range
MI = myocardial infarction
NP = natriuretic peptide
NRI = net reclassification
index
NT-proBNP = N-terminal
fragment of B-type
natriuretic peptide
OR = odds ratio
QICu = corrected
quasi-likelihood under
the independence
model criterion
RCRI = Revised Cardiac
Risk Index
ROC = receiver operating
characteristic
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173included regardless of language, design, sample size, publi-
cation status, or date of publication. We excluded cardiac
surgery studies, pediatric studies, and studies in which NPs
were used as therapy (e.g., nesiritide). Studies collecting
relevant data but not reporting outcomes of interest were
included if outcomes could be obtained from study authors.
The methodology used for this meta-analysis is reported in
Online Appendix 1.
Statistical analysis. The baseline characteristics of the
included patients are reported as mean  SD for continuous
variables and count (percent) for categorical variables. To
identify pre-operative BNP and NT-proBNP thresholds, we
used the approach described by Mazumdar and Glassman
(10) to identify the values corresponding to the smallest p
values that are associated with a statistically significant
association between the outcome of mortality and nonfatal
MI at 30 days after surgery. To categorize post-operative
NP, we used thresholds previously identified as predicting
mortality or nonfatal MI 30 days after surgery (i.e.,
BNP 245 ng/l and NT-proBNP 718 ng/l) (9). Patients
with a measurement below these thresholds were classified as
low risk. Patients with a measurement greater than or equal
to these thresholds were classified as high risk. BNP and
NT-proBNP data sets were then merged and used for
further analyses. NP measurements obtained using fluo-
roimmunoassay methods may differ from those obtained
using radioimmunoassay methods and may affect the
homogeneity of the results (11,12). We therefore assessed
the heterogeneity between BNP and NT-proBNP studies
for the outcome of 30-day mortality or nonfatal MI.
In addition, we explored pre-operative NP using thresholds
previously identified in patients with cardiac failure (i.e.,
BNP<100 and 250 ng/l; NT-proBNP<300, 300 to 900, 900
to 3,000, and>3,000 ng/l) to determinewhether they separated
patients into clinically useful risk groups for the primary outcome
(13–16). The thresholds were explored for the entire cohort of
patients and in vascular and nonvascular groups of patients.
To identify independent predictors of the primary
outcome at 30 days and 180 days after surgery, we used
generalized estimating equations with an exchangeable
correlation structure to take into account study clustering
(17). The baseline model included the following variables:
age, Revised Cardiac Risk Index (RCRI) score 3, type
of surgery (vascular vs. nonvascular), urgency of surgery
(urgent/emergent vs. elective), and study as a clustering
variable. We assessed collinearity using the variance inflation
factor. Variables with a variance inflation factor >10 were
considered to be collinear, and we then excluded one of these
variables from the analysis.
We evaluated pre-operativeNPby adding pre-operativeNP
measurement to the baseline model to create a pre-operative
NP model. The variables in this model included age, RCRI
score3, type of surgery (vascular vs. nonvascular), urgency of
surgery (urgent/emergent vs. elective), and pre-operative NP.
We evaluated post-operative NP by adding a post-operative
NP measurement to the pre-operative NP model.We used the corrected quasi-
likelihood under the indepen-
dence model criterion (QICu)
statistic to compare all model fits
(18). The model with the lowest
QICu was considered preferable.
We used reclassification statistics
(net reclassification index [NRI])
to evaluate how the addition of
NP variables to the baseline
model changed risk classification
(19). On the basis of the NP mea-
surement, patients were reclassified
into different risk categories. The
NRI provides a summary statistic
describing this change in risk
classification, where a positive NRI
reflects an improvement in risk
stratification and a negative NRI
reflects a worsening in risk strati-
fication. For NRI analyses, patients
were risk stratified as <5%, 5% to
10%, >10% to 15%, and >15%
risk for the primary outcome at 30
days after surgery (1). To determine the influence of post-
operative NP drawn later than 1 day after surgery, we
conducted a sensitivity analysis by excluding such studies
and repeating these analyses.
For both BNP and NT-proBNP data sets, we evaluated
the NP change, from pre-operative to post-operative, to
determine whether this added additional prognostic infor-
mation for the prediction of the primary outcome at 30 days
after surgery. The change variables evaluated were (1)
absolute NP change (i.e., post-operative NP – pre-opera-
tive NP); (2) absolute change in the log transformed NP
value (i.e., log[post-operative NP] – log[pre-operative NP]);
(3) fractional change

post-operative NPpre-operative NP
pre-operative NP

; and (4)
log fractional change

logðpost-operative NPÞlogðpre-operative NPÞ
pre-operative NP

.
These four change variables were each evaluated separately
in a model containing the pre-operative and post-operative
NP threshold variables.
We report adjusted odd ratios, corresponding 95%
confidence interval (CI), and associated p values. All p values
are reported to 3 decimal places. The criterion for statistical
significance was set a priori at alpha ¼ 0.05. We used IBM
SPSS Statistics 21.0 (Chicago, Illinois) for all analyses
except for the derivation of the NP thresholds, for which we
used R software version 2.14.1 (R Foundation for Statistical
Computing, Vienna, Austria).Results
Study identification and selection. The study selection
process is shown in Figure 1. We identified 918 citations,
from which 56 were selected for full-text evaluation. From
Figure 1 Study Selection Process
Flow chart demonstrating the results of a structured electronic database search of six databases and grey literature conducted to identify studies reporting on the association of
pre- and post-operative B-type natriuretic peptide (NP) concentrations and post-operative cardiovascular events in adults undergoing noncardiac surgery. BNP ¼ B-type natriuretic
peptide; NT-proBNP ¼ N-terminal fragment of proB-type natriuretic peptide.
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174these, we identified 25 eligible citations (8,20–43). Seven of
these studies were not included in the analysis: Data from 4
papers were included in larger subsequent publications that
we included (29,40–42); one study did not collect data on
death or nonfatal MI (32); we were unable to contact the
authors of one study (28); and one study has been dis-
credited and was therefore not included (Erasmus Investi-
gational Committee, 2012) (26). Individual patient data
were received from all remaining 18 studies and are included
in this systematic review (8,20–25,27,30,31,33–39,43).
Interobserver agreement for study eligibility was excellent
(kappa ¼ 0.86).
Study characteristics and data collection. The character-
istics of the 18 studies included in this systematic review are
reported in Table 1. All studies were prospective observa-
tional cohort studies. Their sample sizes ranged from 22 to
400 patients and included 4 mixed or major general surgery
studies (n ¼ 745); 3 orthopedic studies (n ¼ 309);3 thoracic studies (n ¼ 471); 2 urological studies (n ¼ 77);
and 6 vascular studies (n ¼ 688). All studies measured post-
operative NP within the first day after surgery except for the
studies by Mahla et al. (8) (measured 3 to 5 days after
surgery) and Waliszek et al. (43) (measured 7 days after
surgery) (43). Study quality is reported in Table 2. Data
collection and outcome assessment were blinded in 17 of the
18 studies, and all used a consistent outcome definition over
the course of the study. Fourteen studies conducted
surveillance for post-operative MI by measuring post-
operative troponins.
Data were received on 2,477 patients from 18 studies.
We excluded 298 patients, across all studies, who did
not have both a pre-operative and post-operative NP
measurement. A total of 2,179 patients were included; 8
studies evaluated BNP (n ¼ 619), and 10 studies evaluated
NT-proBNP (n ¼ 1,560). A post-operative sample was
drawn within the first day after surgery from 88% of these
Table 1 Characteristics of Included Studies
First Author, Year (Ref. #)
Patient Population,
Type of Surgery
No. of
Patients
Age of Study
Patients,
mean  SD
Type of Natriuretic
Peptide Assay, Manufacturer Timing and Frequency of Samples
Length of
Follow-up
(Days)
Manikandan et al., 2005 (31) Elective, urological 52 72  9.0 NT-proBNP Elecsys ProBNP, Roche Diagnostics
(Indianapolis, Indiana)
Pre-operative; post-operative: day 1 30
Cardinale et al., 2007 (21) Elective, thoracic 400 62  9.9 NT-proBNP Elecsys ProBNP, Roche Diagnostics Pre-operative; post-operative: 1 h
after surgery
In-hospital
Hoksch et al., 2007 (27) Elective, thoracic 22 67  11.1 BNP Triage BNP-Test, Biosite Diagnostic
(San Diego, California)
Pre-operative; post-operative: days 1-5 270
Mahla et al., 2007 (8) Elective, major vascular 218 70  9.3 NT-proBNP Elecsys ProBNP, Roche Diagnostics Pre-operative; post-operative: days 3-5 826
Schutt et al., 2009 (38) Elective and urgent/emergent,
mixed (60% orthopedic)
75 69  11.0 NT-proBNP Elecsys ProBNP, Roche Diagnostics Pre-operative; post-operative: days 1-3 30
Chong et al., 2010 (23) Urgent/emergent, orthopedic 33 86  9.7 NT-proBNP Elecsys ProBNP, Roche Diagnostics Pre-operative; post-operative: days 1-3 180
Chong et al., 2010 (22) Urgent/emergent, orthopedic 89 80  9.9 NT-proBNP Elecsys ProBNP, Roche Diagnostics Pre-operative; post-operative: days 1-3 730
Cagini et al., 2011 (20) Elective, thoracic 149 66  12.5 BNP Triage BNP, Biosite Diagnostic Pre-operative; post-operative: days 1,3 and 7 360
Cnotliwy et al., 2011 (25) Elective, vascular 100 69  8.5 NT-proBNP Elecsys ProBNP, Roche Diagnostics Pre-operative; post-operative: day 1 30
Radovic et al., 2011 (35) Elective, urological 25 56  8.0 BNP BNP 2, IRMA, CIS bio Internationale,
Gif-Sur-yvette Cedex, France
Pre-operative; post-operative: days 1 and 7 180
Rajagopalan et al., 2011 (36) Elective, major vascular 136 69  9.7 NT-proBNP Elecsys ProBNP, Roche Diagnostics Pre-operative; post-operative: day 1 654
Suttie et al., 2011 (39) Elective, major vascular 45 72  10.4 BNP BNP, Peninsula Laboratories,
Merseyside, United Kingdom
Pre-operative; post-operative: immediately
after surgery, and days 1–4
365
Waliszek et al., 2011 (43) Elective, vascular 40 63.1  10.6 NT-proBNP Elecsys ProBNP, Roche Diagnostics Pre-operative; post-operative: day 7 7
Lurati Buse et al., 2012 (30) Elective, mixed (58% vascular) 380 72  7.9 NT-proBNP Elecsys ProBNP, Roche Diagnostics Pre-operative; post-operative: day 1 and 2 365
Mercantini et al., 2012 (33) Elective, general and orthopedic 205 64  16.3 BNP Triage BNP, Biosite Diagnostic Pre-operative; post-operative: day 1 30
Chong et al., 2012 (24) Emergency, orthopedic 187 77  9.3 NT-proBNP Elecsys ProBNP, Roche Diagnostics Pre-operative; post-operative: days 1–3 365
Park et al., 2012 (34) Elective, mixed (46% orthopedic) 85 69  14.8 BNP Advia Centaur Xp, Siemens (Bayer),
Leverkusen, Germany
Pre-operative; post-operative: day 1 30
Rodseth et al., 2012 (37) Elective, vascular 149 59  12.2 BNP Advia Centaur Xp, Siemens (Bayer) Pre-operative; post-operative: day 1 30
BNP ¼ B-type natriuretic peptide; IRMA ¼ immunoradiometric assay; NT-proBNP ¼ N-terminal fragment of pro B-type natriuretic peptide.
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Table 2 Study Quality Characteristics
First Author, Year (Ref. #)
Data Collection
Blinded to
NP Value
Outcome
Assessment
Blinded to NP
Consistent
Outcome
Definition
Diagnostic Troponin
Threshold Used
During Post-Operative
Screening MI Criteria
Manikandan et al., 2005 (31) Blinded Blinded Yes 4th-generation troponin T
(0.03 ng/ml)
Elevated troponin, and 1 or more
of ECG changes or anginal symptoms
Cardinale et al. 2007 (21) Blinded Blinded Yes No screening performed Not a predefined study end point
Hoksch et al., 2007 (27) Blinded Blinded Yes No screening performed Not a predefined study end point
Mahla et al., 2007 (8) Blinded Blinded Yes 4th-generation troponin T
(0.03 ng/ml)
Elevated troponin and ECG changes
indicative of ischemia
Schutt et al., 2009 (38) Blinded Blinded Yes 4th-generation troponin T
(003 ng/ml)
Elevated troponin, and 1 of ECG
changes or anginal symptoms
Chong et al., 2010 (20) Blinded Blinded Yes Troponin I (0.03 ng/ml) Universal definition of MI
Chong et al., 2010 (23) Blinded Blinded Yes Troponin I (0.03 ng/ml) Universal definition of MI
Cagini et al., 2011 (20) Blinded Blinded Yes No screening performed Not a predefined study end point
Cnotliwy et al., 2011 (25) Blinded Unblinded Yes Troponin I (0.01 ng/ml) Universal definition of MI
Radovic et al., 2011 (35) Blinded Blinded Yes No screening performed Not a predefined study end point
Rajagopalan et al., 2011 (36) Blinded Blinded Yes Troponin-I (0.1 ng/ml) Elevated troponin only
Suttie et al., 2011 (39) Blinded Blinded Yes Troponin T (0.01 ng/ml) Elevated troponin, and 1 of ECG
changes or anginal symptoms
Waliszek et al., 2011 (43) Blinded Blinded Yes Troponin I (0.3 ng/ml) Elevated troponin, and 1 of ECG
changes or anginal symptoms
Lurati Buse et al., 2012 (30) Blinded Blinded Yes 2006–2009: 4th-generation
troponin T (0.03 ng/ml)
Elevated troponin only
2010 onward: 5th-generation
troponin T (0.013 ng/ml)
Mercantini et al., 2012 (33) Blinded Blinded Yes 4th-generation troponin T
(003 ng/ml)
Elevated troponin, and 1 of ECG
changes or anginal symptoms
Chong et al., 2012 (24) Blinded Blinded Yes Troponin I (0.03 ng/ml) Universal definition of MI
Park et al., 2012 (34) Blinded Blinded Yes Troponin T (0.01 ng/ml) Elevated troponin and ECG changes
indicative of ischemia
Rodseth et al., 2012 (37) Blinded Blinded Yes Troponin I (0.1 ng/ml) Elevated troponin only
ECG ¼ electrocardiogram; MI ¼ myocardial infarction; NP ¼ natriuretic peptide.
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176patients (1,921 of 2,179) and within the first 3 days after
surgery in 98% of patients (2,139 of 2,179). The mean (SD)
age was 68 (12) years. Sixty-five percent of patients were
male, 31% of patients had a history of coronary artery
disease, and the most commonly performed surgery was
vascular (40% of the sample). Online Appendix 2 shows the
characteristics of all 2,179 patients. This is subdivided
into the patients who did and did not die or have nonfatal
MI at 30 days after surgery.
Study outcome and determination of pre-operative NP
cut-points. Within 30 days of surgery, 2.8% of patients had
died (n ¼ 62 of 2,179) and 10.8% had died or experienced
nonfatal MI (n ¼ 235 of 2,179). At 180 days, 8.4% of
patients had died (n ¼ 182 of 1,605) and 16.8% had died or
experienced nonfatal MI (n ¼ 366 of 1,617).
The pre-operative NP threshold associated with the
lowest p value for the outcome of death and nonfatal MI
at 30 days after surgery was 92 ng/l (95% CI: 38 to 133)
for BNP (receiver operating characteristic [ROC] area
under the curve [AUC]: 0.71; 95% CI: 0.63 to 0.78) and
300 ng/l (95% CI: 240 to 540) for NT-proBNP (ROC
AUC: 0.69; 95% CI: 0.65 to 0.73). For the merged data
set, the ROC AUC was 0.70 (95% CI: 0.66 to 0.74).
There was no heterogeneity between the BNP or the
NT-proBNP studies for the outcome of 30-day deathand nonfatal MI (I2 ¼ 0) despite two (35,39) of the
eight BNP studies having used a radioimmunoassay
method.
Death or nonfatal MI at 30 days after surgery occurred in
21.8% of patients with a pre-operative NP measurement
above the threshold (n ¼ 166 of 763; likelihood ratio: 2.3)
compared with 4.9% in patients with a measurement below
the threshold (n ¼ 69 of 1,416; likelihood ratio: 0.42). An
elevated pre-operative NP (odds ratio [OR]: 3.40; 95% CI:
2.57 to 4.47; p < 0.001), RCRI 3 (OR: 2.7; 95% CI: 1.81
to 3.96; p < 0.001), and urgent/emergency surgery (OR:
1.60; 95% CI: 0.75 to 3.53; p ¼ 0.216) all predicted death or
nonfatal MI at 30 days (Online Appendix 3).
Death or nonfatal MI at 180 days after surgery occurred
in 37% of patients with a pre-operative NP measurement
above the threshold (n ¼ 235 of 635; likelihood ratio: 2.0)
compared with 13.3% in patients with a measurement below
the threshold (n ¼ 131 of 982; likelihood ratio: 0.53). As
shown in Online Appendix 3, an elevated pre-operative NP
measurement was the strongest predictor of death or
nonfatal MI at 180 days with an OR of 2.6 (95% CI: 2.0
to 3.43; p < 0.001).
Risk prediction improvement with the addition of NP.
Adding a pre-operative NP measurement to the baseline
model improved model fit and risk classification for the
Table 3
Change in Risk Classification for the Probability of Mortality or Nonfatal MI at 30 Days Using a Model Including Pre-Operative NP
Compared With a Model Using Baseline Factors Only
*Primary outcome ¼ composite of mortality of nonfatal MI at 30 days after surgery. yThe addition of NP to the baseline risk model reclassified 91 patients with the primary outcome and 342 patients without
the primary outcome to a higher-risk category, and 53 patients with the primary outcome and 641 patients without the primary outcome to a lower-risk category. zIn patients with the primary outcome,
16.2% were correctly reclassified ([91–53]/235). In patients without the primary outcome, 15.4% were correctly reclassified ([641–342]/1,944). xThe net reclassification improvement is the sum of the
correctly reclassified patients who did and did not survive (i.e., 16.2% + 15.4% ¼ 31.6%).
MI ¼ myocardial infarction; NP ¼ natriuretic peptide.
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177prediction of the primary outcome at 30 days (QICu:
1,352.95 to 1,280.16; NRI: 32%; p < 0.001) and 180 days
(QICu: 1,376 to 1,320.42; NRI: 18%; p < 0.001) after
surgery (Table 3). Adding a post-operative NP measurement
to the pre-operative NP model further improved model fit
and risk classification at both 30 days (QICu: 1,280.16 toTable 4
Change in Risk Classification for the Probability of Mortality
Post-operative NP Compared With Baseline and Pre-Operativ
*Primary outcome ¼ composite of mortality of nonfatal MI at 30 days after surgery. yThe addition of NP to
the primary outcome to a higher-risk category, and 28 patients with the primary outcome and 316 pati
19.6% were correctly reclassified ([74–28]/235). In patients without the primary outcome, 0.6% were
correctly reclassified patients who did and did not survive (i.e., 19.6% + 0.6% ¼ 20.2%).
MI ¼ myocardial infarction; NP ¼ natriuretic peptide.1,204.06; NRI: 20%; p < 0.001) and 180 days (QICu:
1,320.42 to 1,300.09; NRI: 11%; p ¼ 0.003) (Table 4). The
results of the sensitivity analysis that excluded the two
studies measuring post-operative NP after the first post-
operative day did not differ appreciably from the primary
results (Online Appendix 4).or Nonfatal MI at 30 Days Using a Model Including Pre- and
e NP Model Only
the baseline risk model reclassified 74 patients with the primary outcome and 305 patients without
ents without the primary outcome to a lower-risk category. zIn patients with the primary outcome,
correctly reclassified ([316–305]/1,944). xThe net reclassification improvement is the sum of the
Table 5
Variables Evaluated in the Final Generalized Estimating Equation Model for an Association
With the Composite Outcome of Mortality or Nonfatal MI After Surgery
Outcome Variable
Adjusted OR
(95% CI) p Value
Death or nonfatal MI
30 days after surgery
Post-operative elevated NP 3.70 (2.18–6.24) <0.001*
RCRI 3 2.30 (1.59–3.19) <0.001*
Pre-operative elevated NP 1.90 (1.44–2.40) <0.001*
Urgent/emergent surgery 1.40 (0.72–2.64) 0.337
Vascular surgery 1.30 (0.63–2.62) 0.484
Age (per year) 1.00 (0.99–1.03) 0.096
Death or nonfatal MI
180 days after surgery
Post-operative elevated NP 2.20 (1.85–2.65) <0.001*
RCRI 3 2.10 (1.87–2.52) <0.001*
Pre-operative elevated NP 1.90 (1.38–2.58) <0.001*
Age (per year) 1.01 (1.00–1.02) 0.016*
Vascular surgery 1.40 (0.77–2.47) 0.590
Urgent/emergent surgery 0.60 (0.22–1.86) 0.545
*p < 0.05.
CI ¼ confidence interval; GEE ¼ generalized estimating equation; MI ¼ myocardial infarction; NP ¼ natriuretic peptide; OR ¼ odds ratio;
RCRI ¼ Revised Cardiac Risk Index.
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178In the final model, independent predictors for the study
outcome at 30 days were elevated post-operative NP (OR:
3.70; 95% CI: 2.18 to 6.24; p < 0.001), RCRI 3 (OR:
2.30; 95% CI: 1.59 to 3.19; p < 0.001), and elevated pre-
operative NP (OR: 1.90; 95% CI: 1.44 to 2.40; p < 0.001).
At 180 days, the independent predictors were elevated
post-operative NP (OR: 2.20; 95% CI: 1.85 to 2.65; p <
0.001), RCRI 3 (OR: 2.20; 95% CI: 1.87 to 2.52; p <
0.001), elevated pre-operative NP (OR: 1.90; 95% CI: 1.38
to 2.58; p < 0.001), and age (OR: 1.01; 95% CI: 1.00 to
1.02; p ¼ 0.016). These results are reported in Table 5. We
identified no significant collinearity between variables.
NP change. After surgery, NP measurements increased in
76% of patients (n ¼ 1,653), with a median BNP increase of
66 ng/l (interquartile range [IQR]: 123 ng/l) and an NT-
proBNP increase of 323 ng/l (IQR: 874 ng/l). NP
decreased in 23% of patients (n ¼ 507), with a median BNP
decrease of 15 ng/l (IQR: 64 ng/l) and an NT-proBNP
decrease of 53 ng/l (IQR: 153 ng/l). In both BNP and
NT-proBNP data sets, the four change variables were each
separately evaluated in a generalized estimating equation
model containing the derived pre- and post-operative NP
thresholds. In both data sets, none of the change variables
were significant predictors of the primary study outcome at
30 days after surgery (Online Appendix 5).
Our exploration of traditional NP thresholds found that
patients with pre-operative BNP values of 0 to 100, >100 to
250, and >250 ng/l demonstrated the composite of 30-day
mortality or nonfatal MI at a rate of 5.1%, 11.6%, and
26.3%, respectively. Patients with pre-operative NT-
proBNP values of 0 to 300, >300 to 900, >900 to 3,000,
and >3,000 ng/l demonstrated the same outcome at a rate of
5.2%, 16.1%, 26%, and 39.5%, respectively. These BNP and
NT-proBNP results, together with the breakdown for
vascular and nonvascular surgery groups of patients, are
shown in Online Appendix 6.Discussion
This systematic review and individual patient-level data
analysis demonstrate that adding a post-operative NP
measurement to a pre-operative risk model that included
pre-operative NP measurement improved the prediction of
mortality or nonfatal MI at 30 or180 days after noncardiac
surgery.
The potential for NP measurement in pre-operative risk
stratification lies in its ability to integrate the impact of
multiple pre-operative pathophysiological processes into
a single measurement (2,3). Previous meta-analyses suggest
that a single elevated pre-operative NP measurement is
highly predictive of serious cardiovascular complications
after noncardiac surgery and may be a better predictor of
these events than the RCRI (4,5). Measuring NP in adults
undergoing major noncardiac surgery thus significantly
improves pre-operative risk stratification and could easily
be incorporated into clinical practice, particularly in
patients undergoing major vascular, intrathoracic, ortho-
pedic, or intraperitoneal surgery, and would allow physi-
cians to plan prophylactic strategies in patients identified
as high risk.
In our analysis, a post-operative NP measurement was the
strongest predictor of mortality or nonfatal MI after
noncardiac surgery, and the addition of a post-operative NP
measurement augmented the identification of at-risk
patients. Post-operative NP elevations might identify
patients who will develop major cardiovascular complica-
tions, allowing physicians to intervene by administering
beta-blockers, aspirin, or statins. However, further studies
are required to ascertain whether interventions in response to
NP measurements will improve patient outcomes. What
remains unclear, and what could not be determined from
this analysis, is the extent to which post-operative NP
elevation correlates with post-operative troponin elevation.
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179NP elevation may precede troponin elevation, for example,
when the patient is fluid overloaded and in cardiac failure, or
NP elevation may occur together with troponin elevation
when the myocardium is exposed to ischemia. In such cases,
it remains unclear whether measuring NP provides addi-
tional information to that provided by post-operative
troponin alone (1,44).
The strengths of this review lie in its rigorous method-
ology that includes a published review protocol, an extensive
literature search, and adherence to reporting standards for
systematic reviews. A particular strength is our success in
obtaining individual-level patient data on 2,179 patients.
Further, our analysis has accounted for the clustering effect
of the contributing studies, and we surpassed 10 events per
variable in all our regression models, thus ensuring stable
measures of association (45).
Study limitations. A limitation of this analysis is that post-
operative NP sampling was not performed at the same time
point in all studies. More than 90% of patients included in the
primary analysis had NP drawn within the first day after
surgery, and 98% within the first 3 days after surgery. The
results of the sensitivity analysis conducted using only studies
where NP sampling was performed within the first day of
surgery were not appreciably different from the primary
analysis. Therefore, it is likely that these results are represen-
tative of what can be expected by sampling NP early after
surgery. No other post-operative variables besides NP could
be evaluated in this analysis, and as a result we are unable to
adjust for factors such as post-operative renal dysfunction,
which is known to elevate NP. Two BNP studies used radio-
immunoassay analysis methods (35,39), and the remaining six
BNP studies used fluoroimmunoassay (20,27,31,33,34,37).
Although our analysis found no heterogeneity between the
BNP studies for the primary outcome, our choice to pool BNP
concentrations obtained from diverse assays with varying
degrees of precision (11,12) should be seen as a limitation.
Four studies (n ¼ 496) did not conduct routine post-
operative troponin surveillance (20,21,27,35); thus, it is
possible that the incidence of post-operative MI may be
higher than what we have reported. Most post-operative
troponin elevations occur within the first 48 to 72 h after
surgery (46). Although 88% of post-operative NP
measurements were made within the first day after surgery,
we are unable to determine the exact relationship between
post-operative NP elevation and post-operative troponin
elevation. All studies used an elevated troponin as part of
their definition of post-operative MI, with two studies
making the diagnosis on the basis of troponin elevation
alone (30,37).Conclusions
The addition of a post-operative NP measurement to a pre-
operative risk model that includes pre-operative NP
measurement significantly improves the prediction of thecomposite outcome of mortality or nonfatal MI within 30
days or 180 days after noncardiac surgery.Acknowledgments
The authors thank Drs. Verhagen and Hoeks, Erasmus
University Medical Center; Dr. Jan Brozekj, Departments of
Clinical Epidemiology and Biostatistics and Medicine,
McMaster University; and Dr. David McDonagh, Depart-
ment of Anesthesiology, Duke University Medical Center.
Reprint requests and correspondence: Dr. Reitze N. Rodseth,
Department of Anaesthetics, Nelson R. Mandela School of
Medicine, University of KwaZulu-Natal, Private Bag 7, Congella,
4013, South Africa. E-mail: ReitzeRodseth@gmail.com.REFERENCES
1. Devereaux PJ, Chan MT, Alonso-Coello P, et al. Association between
postoperative troponin levels and 30-day mortality among patients
undergoing noncardiac surgery. JAMA 2012;307:2295–304.
2. Struthers A, Lang C. The potential to improve primary prevention in
the future by using BNP/N-BNP as an indicator of silent ‘pancardiac’
target organ damage: BNP/N-BNP could become for the heart what
microalbuminuria is for the kidney. Eur Heart J 2007;28:1678–82.
3. Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the
heart as an endocrine organ: physiological role and clinical utility of
cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol 2011;
301:H12–20.
4. Rodseth RN, Lurati Buse GA, Bolliger D, et al. The predictive ability
of pre-operative B-type natriuretic peptide in vascular patients for major
adverse cardiac events: an individual patient data meta-analysis. J Am
Coll Cardiol 2011;58:522–9.
5. Karthikeyan G, Moncur RA, Levine O, Heels-Ansdell D, Chan MT,
Alonso-Coello P, et al. Is a pre-operative brain natriuretic peptide or
N-terminal pro-B-type natriuretic peptide measurement an indepen-
dent predictor of adverse cardiovascular outcomes within 30 days of
noncardiac surgery? A systematic review and meta-analysis of obser-
vational studies. J Am Coll Cardiol 2009;54:1599–606.
6. Biccard BM, Lurati Buse GA, Burkhart C, Cuthbertson BH,
Filipovic M, Gibson SC, et al. The influence of clinical risk factors on
pre-operative B-type natriuretic peptide risk stratification of vascular
surgical patients. Anaesthesia 2012;67:55–9.
7. Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-operative
cardiac risk assessment and perioperative cardiac management in
non-cardiac surgery. Eur Heart J 2009;30:2769–812.
8. Mahla E, Baumann A, Rehak P, et al. N-terminal pro-brain natriuretic
peptide identifies patients at high risk for adverse cardiac outcome after
vascular surgery. Anesthesiology 2007;106:1088–95.
9. Rodseth RN, Biccard BM, Le Manach Y, et al. Postoperative B-type
natriuretic peptide for prediction of major cardiac events in patients
undergoing noncardiac surgery – systematic review and individual
patient meta-analysis. Anesthesiology 2013;119:270–83.
10. Mazumdar M, Glassman JR. Categorizing a prognostic variable: review
of methods, code for easy implementation and applications to decision-
making about cancer treatments. Stat Med 2000;19:113–32.
11. Clerico A, Zucchelli GC, Pilo A, Emdin M. Clinical relevance of
biological variation of B-type natriuretic peptide. Clin Chem 2005;51:
925–6.
12. Clerico A, Zaninotto M, Prontera C, et al. State of the art of BNP and
NT-proBNP immunoassays: the CardioOrmoCheck study. Clin Chim
Acta 2012;414:112–9.
13. Rodseth RN. B type natriuretic peptide–a diagnostic breakthrough in
peri-operative cardiac risk assessment? Anaesthesia 2009;64:165–78.
14. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of
B-type natriuretic peptide in the emergency diagnosis of heart failure.
N Engl J Med 2002;347:161–7.
Rodseth et al. JACC Vol. 63, No. 2, 2014
BNP and Risk in Noncardiac Surgery January 21, 2014:170–80
18015. Korenstein D, Wisnivesky JP, Wyer P, Adler R, Ponieman D,
McGinn T, et al. The utility of B-type natriuretic peptide in the
diagnosis of heart failure in the emergency department: a systematic
review. BMC Emerg Med 2007;7:6.
16. Januzzi JL Jr., Chen-Tournoux AA, Moe G. Amino-terminal
pro-B-type natriuretic peptide testing for the diagnosis or exclusion of
heart failure in patients with acute symptoms. Am J Cardiol 2008;101:
29–38.
17. Hardin JW, Hilbe J. Generalized Estimating Equations. Boca Raton,
FL: Chapman & Hall/CRC, 2003.
18. Pan W. Akaike’s information criterion in generalized estimating
equations. Biometrics 2001;57:120–5.
19. Pencina MJ, D’Agostino RB Sr., Steyerberg EW. Extensions of net
reclassification improvement calculations to measure usefulness of new
biomarkers. Stat Med 2011;30:11–21.
20. Cagini L, Capozzi R, Tassi V, et al. Fluid and electrolyte balance after
major thoracic surgery by bioimpedance and endocrine evaluation. Eur
J Cardiothorac Surg 2011;40:e71–6.
21. Cardinale D, Colombo A, Sandri MT, et al. Increased perioperative
N-terminal pro-B-type natriuretic peptide levels predict atrial fibrillation
after thoracic surgery for lung cancer. Circulation 2007;115:1339–44.
22. Chong CP, Ryan JE, Van Gaal WJ, et al. Usefulness of N-terminal
probrain natriuretic peptide to predict postoperative cardiac complica-
tions and long-term mortality after emergency lower limb orthopedic
surgery. Am J Cardiol 2010;106:865–72.
23. Chong CP, van Gaal WJ, Ryan JE, Burrell LM, Savige J, Lim WK.
Troponin I and NT-proBNP (N-terminal pro-brain natriuretic
peptide) do not predict 6-month mortality in frail older patients
undergoing orthopedic surgery. J Am Med Dir Assoc 2010;11:415–20.
24. Chong CP, Lim WK, Velkoska E, van Gaal WJ, Ryan JE, Savige J,
et al. N-terminal pro-brain natriuretic peptide and angiotensin-
converting enzyme-2 levels and their association with postoperative
cardiac complications after emergency orthopedic surgery. Am J Car-
diol 2012;109:1365–73.
25. Cnotliwy M, Kazimierczak A, Sledz M, Biernacka J, Zukowski M. The
usefulness of N-terminal pro-brain natriuretic peptide and cardiac
troponin measurement in the prediction of cardiac morbidity after
carotid endarterectomy. Acta Angiol 2011;17:199–208.
26. Goei D, Van Kuijk JP, Flu WJ, et al. Usefulness of repeated
N-terminal pro-B-type natriuretic peptide measurements as incre-
mental predictor for long-term cardiovascular outcome after vascular
surgery. Am J Cardiol 2011;107:609–14.
27. Hoksch B, Fahrner R, Schmid RA. Procalcitonin and brain natriuretic
peptide as parameters in the postoperative course of patients with
major pulmonary resection. Interact Cardiovasc Thorac Surg 2007;6:
155–8.
28. Hou JL, Gao K, Li M, et al. Increased N-terminal pro-brain natriuretic
peptide level predicts atrial fibrillation after surgery for esophageal
carcinoma. World J Gastroenterol 2008;14:2582–5.
29. Jarai R, Mahla E, Perkmann T, et al. Usefulness of pre-operative
copeptin concentrations to predict post-operative outcome after major
vascular surgery. Am J Cardiol 2011;108:1188–95.
30. Lurati Buse GA, Schumacher P, Seeberger E, et al. Randomized
comparison of sevoflurane versus propofol to reduce perioperative
myocardial ischemia in patients undergoing noncardiac surgery.
Circulation 2012;126:2696–704.
31. Manikandan R, Nathaniel C, Lewis P, et al. Troponin T and
N-terminal pro-brain natriuretic peptide changes in patients under-
going transurethral resection of the prostate. J Urol 2005;174:1892–5.
32. McDonagh DL, Mathew JP, White WD, et al. Cognitive function
after major noncardiac surgery, apolipoprotein E4 genotype, and
biomarkers of brain injury. Anesthesiology 2010;112:852–9.33. Mercantini P, Di Somma S, Magrini L, et al. Preoperative brain
natriuretic peptide (BNP) is a better predictor of adverse cardiac events
compared to preoperative scoring system in patients who underwent
abdominal surgery. World J Surg 2012;36:24–30.
34. Park JH, Shin GJ, Ryu JI, Pyun WB. Postoperative B-type natriuretic
peptide levels associated with prolonged hospitalization in hypertensive
patients after non-cardiac surgery. Korean Circ J 2012;42:521–7.
35. Radovic M, Damjanovic S, Nale D, Micic S, Vucovic D, Radovic M.
Modulation of aldosterone release by epidural analgesia impacts brain
natriuretic peptide: a link to stress cardiomyopathy? Pilot study. Clin
Endocrinol 2011:649–56.
36. Rajagopalan S, Croal BL, Reeve J, Bachoo P, Brittenden J. N-terminal
pro-B-type natriuretic peptide is an independent predictor of all-cause
mortality and MACE after major vascular surgery in medium-term
follow-up. Eur J Vasc Endovasc Surg 2011;41:657–62.
37. Rodseth RN, de Vascocellos K, Naidoo P, Biccard BM. Early post-
operative BNP does not predict postoperative cardiac events within 30
days of vascular surgery. South Afr J Anaesth Analg 2013;19:60–5.
38. Schutt RC, Cevik C, Phy MP. Plasma N-terminal prohormone brain
natriuretic peptide as a marker for postoperative cardiac events in high-
risk patients undergoing noncardiac surgery. Am J Cardiol 2009;104:
137–40.
39. Suttie SA, Mofidi R, McCallum R, et al. Immediately postoperative
B-type natriuretic peptide and its predictive value. Ann Vasc Surg
2011;25:248–55.
40. Talucci V, Magrini L, Petrucciani N, et al. BNP measurement pre- and
post-noncardiac surgery as prognostic factor of cardiovascular events in
hypertensive patients. J Hypertens 2010;28:e188–9.
41. Talucci V, Magrini L, Scarinci A, et al. Evaluation of brain natriuretic
peptide (BNP) role as prognostic factor for cardiovascular outcomes in
patients undergoing non-cardiac surgery. Eur Heart J 2010. Paper
presented at: European Society of Cardiology 2010, Stockholm,
Sweden, August 28, 2010, to September 1, 2010.
42. Van Kuijk JP, Flu WJ, Hoeks SE, et al. Repeated N-terminal pro B-
type natriuretic peptide measurements as incremental predictor for
long-term cardiovascular outcome after vascular surgery. Eur Heart J
2010. Paper presented at: European Society of Cardiology 2010,
Stockholm, Sweden, August 28, 2010 to September 1, 2010.
43. Waliszek M, Waliszek-Iwanicka A, Grycewicz T, et al. Prognostic
value of plasma N-terminal pro-B-type natriuretic peptide concentra-
tion in patients with normal and impaired left ventricular systolic
function undergoing surgery for abdominal aortic aneurysm. Arch Med
Sci 2011;7:642–7.
44. Bolliger D, Seeberger MD, Lurati Buse GA, et al. A preliminary report
on the prognostic significance of preoperative brain natriuretic peptide
and postoperative cardiac troponin in patients undergoing major
vascular surgery. Anesth Analg 2009;108:1069–75.
45. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR.
A simulation study of the number of events per variable in logistic
regression analysis. J Clin Epidemiol 1996;49:1373–9.
46. Devereaux PJ, Xavier D, Pogue J, et al. Characteristics and short-term
prognosis of perioperative myocardial infarction in patients undergoing
noncardiac surgery: a cohort study. Ann Intern Med 2011;154:523–8.
Key Words: anesthesia - myocardial infarction - natriuretic peptides -
risk factors - surgery.
APPENDIX
For supplemental material, please see the online version of this article.Go to http://cme.jaccjournals.org
to take the CME quiz for this article.
